De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
China Resources Medical Holdings Inkomsten in het verleden
Verleden criteriumcontroles 0/6
China Resources Medical Holdings's earnings have been declining at an average annual rate of -3.9%, while the Healthcare industry saw earnings growing at 3.6% annually. Revenues have been growing at an average rate of 36.4% per year. China Resources Medical Holdings's return on equity is 4.7%, and it has net margins of 2.9%.
Belangrijke informatie
-3.9%
Groei van de winst
-4.1%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 15.7% |
| Inkomstengroei | 36.4% |
| Rendement op eigen vermogen | 4.7% |
| Nettomarge | 2.9% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe China Resources Medical Holdings geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 9,970 | 294 | 1,069 | 0 |
| 31 Mar 24 | 10,039 | 276 | 1,061 | 0 |
| 31 Dec 23 | 10,108 | 258 | 1,053 | 0 |
| 30 Sep 23 | 9,958 | 338 | 1,025 | 0 |
| 30 Jun 23 | 9,809 | 419 | 997 | 0 |
| 31 Mar 23 | 8,855 | 342 | 931 | 0 |
| 31 Dec 22 | 7,901 | 266 | 864 | 0 |
| 30 Sep 22 | 6,891 | 365 | 779 | 0 |
| 30 Jun 22 | 5,881 | 463 | 695 | 0 |
| 31 Mar 22 | 5,164 | 441 | 630 | 0 |
| 31 Dec 21 | 4,447 | 418 | 566 | 0 |
| 30 Sep 21 | 4,031 | 410 | 504 | 0 |
| 30 Jun 21 | 3,615 | 402 | 441 | 0 |
| 31 Mar 21 | 3,183 | 356 | 400 | 0 |
| 31 Dec 20 | 2,751 | 310 | 358 | 0 |
| 30 Sep 20 | 2,404 | 313 | 306 | 0 |
| 30 Jun 20 | 2,058 | 315 | 253 | 0 |
| 31 Mar 20 | 2,087 | 353 | 253 | 0 |
| 31 Dec 19 | 2,115 | 391 | 254 | 0 |
| 30 Sep 19 | 2,112 | 401 | 244 | 0 |
| 30 Jun 19 | 2,108 | 412 | 235 | 0 |
| 31 Mar 19 | 2,084 | 421 | 229 | 0 |
| 31 Dec 18 | 2,059 | 431 | 223 | 0 |
| 30 Sep 18 | 1,996 | 364 | 225 | 0 |
| 30 Jun 18 | 1,932 | 298 | 227 | 0 |
| 31 Mar 18 | 1,905 | 360 | 219 | 0 |
| 31 Dec 17 | 1,878 | 421 | 212 | 0 |
| 30 Sep 17 | 1,784 | -446 | 204 | 0 |
| 30 Jun 17 | 1,690 | -1,312 | 196 | 0 |
| 31 Mar 17 | 1,611 | -1,410 | 184 | 0 |
| 31 Dec 16 | 1,533 | -1,507 | 172 | 0 |
| 30 Sep 16 | 1,504 | -656 | 167 | 0 |
| 30 Jun 16 | 1,475 | 196 | 163 | 0 |
| 31 Mar 16 | 1,424 | 181 | 156 | 0 |
| 31 Dec 15 | 1,372 | 167 | 150 | 0 |
| 30 Sep 15 | 1,337 | 208 | 124 | 0 |
| 30 Jun 15 | 1,302 | 249 | 97 | 0 |
| 31 Mar 15 | 1,254 | 240 | 91 | 0 |
| 31 Dec 14 | 1,206 | 230 | 86 | 0 |
| 30 Sep 14 | 1,090 | 176 | 85 | 0 |
| 30 Jun 14 | 975 | 122 | 84 | 0 |
| 31 Mar 14 | 931 | 106 | 79 | 0 |
| 31 Dec 13 | 887 | 90 | 74 | 0 |
Kwaliteitswinsten: 1PH has a large one-off loss of CN¥370.2M impacting its last 12 months of financial results to 30th June, 2024.
Groeiende winstmarge: 1PH's current net profit margins (2.9%) are lower than last year (4.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 1PH's earnings have declined by 3.9% per year over the past 5 years.
Versnelling van de groei: 1PH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 1PH had negative earnings growth (-29.8%) over the past year, making it difficult to compare to the Healthcare industry average (30.9%).
Rendement op eigen vermogen
Hoge ROE: 1PH's Return on Equity (4.7%) is considered low.